1. Home
  2. HIT vs RLYB Comparison

HIT vs RLYB Comparison

Compare HIT & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Health In Tech Inc.

HIT

Health In Tech Inc.

HOLD

Current Price

$1.00

Market Cap

74.1M

Sector

Finance

ML Signal

HOLD

Logo Rallybio Corporation

RLYB

Rallybio Corporation

N/A

Current Price

$16.84

Market Cap

86.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HIT
RLYB
Founded
1964
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Specialty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
74.1M
86.6M
IPO Year
2024
2021

Fundamental Metrics

Financial Performance
Metric
HIT
RLYB
Price
$1.00
$16.84
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$3.25
N/A
AVG Volume (30 Days)
67.6K
20.6K
Earning Date
05-12-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
100.00
N/A
EPS
N/A
6.16
Revenue
$33,327,511.00
$858,000.00
Revenue This Year
$41.00
N/A
Revenue Next Year
$69.63
N/A
P/E Ratio
N/A
$2.76
Revenue Growth
70.99
43.00
52 Week Low
$0.85
$0.48
52 Week High
$4.01
$17.57

Technical Indicators

Market Signals
Indicator
HIT
RLYB
Relative Strength Index (RSI) 40.94 54.07
Support Level $0.99 $15.68
Resistance Level $1.16 $17.34
Average True Range (ATR) 0.06 0.48
MACD -0.01 0.02
Stochastic Oscillator 10.10 49.33

Price Performance

Historical Comparison
HIT
RLYB

About HIT Health In Tech Inc.

Health In Tech Inc is an AI-enabled insurance technology platform company that offers a marketplace that improves processes in the healthcare industry through vertical integration, process simplification, and automation. By removing friction and complexities, it streamlines the underwriting, sales, and service process for insurance companies, licensed brokers, Managing General Underwriter (MGUs), and third-party administrators (TPAs). The company's platform serves as a marketplace for brokers, TPAs, MGUs and carriers with self-funded health insurance options for employers. The platform includes functions such as plan customization, stop-loss quoting, underwriting, claims administration, and reporting integration.

About RLYB Rallybio Corporation

Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.

Share on Social Networks: